Work

An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function

Year: 2011

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-011-1733-6

Authors: Cindy L. O’Bryant, Paul Haluska, Lee Rosen, Ramesh K. Ramanathan, Balaji Venugopal, Stephen Leong, Ramesh Boinpally, Amy Franke, Karsten Witt, Jeffry Evans, Chandra Belani, S. Gail Eckhardt, Suresh Ramalingam

Institutions: University of Colorado Cancer Center, University of Colorado Denver, Mayo Clinic, UPMC Hillman Cancer Center, Beatson West of Scotland Cancer Centre, University of Glasgow, University of Pittsburgh

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Cancer Research UK, National Cancer Institute

Award: G6591838237

OpenAlex ID: W1963871015

FWCI: 2.37

Cites: 25

Cited by: 25

Related to: 10